Nina Dusilkova

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4743821/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Oncogenic MicroRNAs: miR-155, miR-19a, miR-181b, and miR-24 enable monitoring of early breast cancer in serum. BMC Cancer, 2014, 14, 448.	2.6	149
2	Plasma miR-155, miR-203, and miR-205 are Biomarkers for Monitoring of Primary Cutaneous T-Cell Lymphomas. International Journal of Molecular Sciences, 2017, 18, 2136.	4.1	33
3	Oncogenic microRNA-155 and its target PU.1: an integrative gene expression study in six of the most prevalent lymphomas. International Journal of Hematology, 2015, 102, 441-450.	1.6	17
4	Somatic mutation dynamics in MDS patients treated with azacitidine indicate clonal selection in patients-responders. Oncotarget, 2017, 8, 111966-111978.	1.8	8
5	Analysis of 5-Azacytidine Resistance Models Reveals a Set of Targetable Pathways. Cells, 2022, 11, 223.	4.1	5
6	Erythroid Transcription Factor GATA-1 Binds and Represses PU.1 Gene – Candidate Mechanism Of Epigenetic Repression Of PU.1 and Inefficient Erythropoiesis In MDS. Blood, 2013, 122, 1558-1558.	1.4	0
7	Somatic Mutation-Detecting Algorithm Enables Analysis of MDS Patients during Azacitidine Therapy. Blood, 2014, 124, 5600-5600.	1.4	0
8	Clonal Architecture of MDS Somatic Mutations Dynamically Changes during Azacitidine Therapy and Has Very Limited Potential to Predict Patient Outcome. Blood, 2016, 128, 4294-4294.	1.4	0
9	Myristoylated Alanine-Rich C-Kinase Substrate (MARCKS) Is a New Biomarker for Mantle Cell Lymphoma: Expression, Localization, and Phosphorylation Study. Blood, 2016, 128, 1767-1767.	1.4	0
10	Randomized Open-Labeled Academic Trial Comparing Standard AZA Therapy with Combination of G-CSF with AZA in High Risk MDS Patients - Interim Analysis. Blood, 2019, 134, 1729-1729.	1.4	0